Another limitation of current radioligand therapies in AML is the associated damage to marrow due to higher expression of explored targets (e.g. CD33, CD123, and CLL-1) on normal myeloid cells and progenitors5. This evidence concerns the gene CD33 and acute myeloid leukemia.